Effect of Plant Stanol Esters on Blood Lipids

The Effect of Plant Stanol Esters on Serum Total and Lipoproteins Lipids, Non-cholesterol Sterols and Apolipoproteins in Subjects With Elevated Blood Lipid Concentration

Status

Completed

Phases

Study type

Interventional

Source

ClinicalTrials.gov

Registry ID

NCT00920894

Enrollment

112

Registered

2009-06-15

Start date

2009-01-31

Completion date

2009-11-30

Last updated

2009-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Elevated Blood Lipids

Brief summary

This study aims to measure the effect of plant stanol esters on serum total and lipoproteins lipids, non-cholesterol sterols and apolipoproteins in subjects with elevated fasting blood lipid concentrations

Detailed description

The link between high serum low-density lipoprotein (LDL) cholesterol and cardiovascular disease has long been recognized. Dietary plant stanol esters have been shown to effectively reduce serum levels of total and LDL cholesterol. Plant stanols decrease the absorption of both biliary and dietary cholesterol from the small intestine and thereby reduce serum LDL cholesterol levels. This study aims to verify the effect of plant stanol esters on blood lipids. Subjects with elevated fasting blood lipid concentrations will be randomized to study groups. The groups consume yoghurt type minidrink containing plant stanol ester (2 g plant stanols per day) or similar minidrink without plant stanol esters. After 10 weeks study period serum total and lipoproteins lipids, non-cholesterol sterols and apolipoproteins will by analyzed.

Interventions

DIETARY_SUPPLEMENTplant stanol ester

the effect of plant stanol esters on plasma lipids

Study design

Allocation

RANDOMIZED

Intervention model

PARALLEL

Primary purpose

TREATMENT

Masking

DOUBLE (Subject, Investigator)

Eligibility

Sex/Gender

ALL

Age

20 Years to 70 Years

Healthy volunteers

Inclusion criteria

* Elevated blood lipids * Body Mass Index \< 35 kg/m2 * Stable body weight

Exclusion criteria

* Receiving medications or supplements other than stable statin therapy known to affect lipid metabolism * Severe obesity * Hyperglycemia * Severe diseases (inc. diabetes, unstable CVD, malignant disease, inflammatory disease, gastrointestinal disease) * Hepatic, kidney or thyroid disease or disorder * Pregnancy or breast feeding * Severe intolerance or allergy to any ingredient of test product

Design outcomes

Primary

Measure	Time frame
plasma lipids	10 weeks

Secondary

Measure	Time frame
plasma lipoprotein lipids non-cholesterol sterols	10 weeks

Countries

Finland

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026